Research programme: diabetes cell therapies - Sernova

Alternative Names: Cell Pouch™ - diabetes cell therapy; Sertolin™ - diabetes cell therapy

Latest Information Update: 04 Nov 2017

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator JDRF; Sertoli Technologies
Developer Sernova Corp
Class Cell therapies
Mechanism of Action Immunomodulators; Pancreatic beta cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Type 1 diabetes mellitus

Most Recent Events

04 Nov 2017 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in Canada (SC, Implant)
10 Sep 2015 Sernova in-licenses proprietary stem cell derived technologies from the University Health Network (UHN) of Toronto for insulin-dependent diabetes
23 Apr 2015 Sernova receives patent allowance for Cell Pouch™ technology in USA

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.